Apollomics (APLM) announced the completion of enrollment in its Phase 3 bridging study evaluating uproleselan, APL-106, an investigational, first-in-class E-selectin antagonist, added to a standard chemotherapy regimen for the treatment of adults with relapsed or refractory acute myeloid leukemia. This Phase 3 bridging study is being performed in China with Chinese r/r AML patients. Apollomics licensed uproleselan from GlycoMimetics (GLYC), including the rights to clinical development, production and commercial sales in the Greater China market. Guo-Liang Yu, Chairman and CEO of Apollomics said, “As a potential first-in-class therapeutic that addresses chemoresistance, uproleselan has the potential to be transformative in patients with AML. I would also like to thank our investigators, staff, as well as our clinical team and CRO partners, for their commitment to completing this important milestone.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on APLM:
- Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
- Apollomics to Present at the 2024 Biotech Showcase
- Apollomics presents interim data from ongoing Phase 2 trials with vebreltinib
- Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
- Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)